Wake Forest University Health Sciences, Dermatology
Welcome,         Profile    Billing    Logout  
 21 Trials 
14 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Feldman, Steven R
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
NCT05981118: Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)

Enrolling by invitation
2/3
40
US
Betamethasone dipropionate 0.05%, Tapinarof
Wake Forest University Health Sciences, Dermavant Sciences, Inc.
ICD10 Code L40.9 for Psoriasis
07/25
12/25
NCT04275999: Rosacea and Ivermectin

Active, not recruiting
2
30
US
ivermectin, digital interaction, digital interaction survey with ivermectin, GPSkin, GPSkin Barrier®
Wake Forest University Health Sciences, Galderma R&D
Rosacea
03/25
11/25
NCT05582434: Experience With Topical Acne Treatment

Recruiting
1
72
US
Adapalene Gel, Differin, Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel, Differin and ONEXTON, adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day., Differin, Epsolay, Clindamycin
Wake Forest University Health Sciences, Bausch Health Americas, Inc.
Acne
05/25
11/25
NCT05601492: Adherence to Otezla

Not yet recruiting
1
84
US
Otezla - Standard Care, Apremilast, Reminder Text Intervention with apremilast, Otezla, Extended Consultation for apremilast
Wake Forest University Health Sciences, Amgen
Psoriasis
09/25
12/25
NCT05570955: Deucravacitinib Adherence Study

Recruiting
N/A
40
US
Text reminder
Wake Forest University Health Sciences, Bristol-Myers Squibb
Psoriasis
07/25
12/25
NCT04341623: Xerosis and Use of Topical Moisturizer

Active, not recruiting
N/A
35
US
Cetaphil Pro Eczema moisturizer, Electronic interaction, GPSkin
Wake Forest University Health Sciences, Galderma R&D
Xerosis Due to Atopic Dermatitis
02/25
12/25
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
McMichael, Amy
NCT03569956: Shaving Satisfaction in Males With Skin Irritation From Shaving

Active, not recruiting
N/A
40
US
556 Razor
Wake Forest University Health Sciences, Procter and Gamble
Pseudofolliculitis Barbae
04/19
02/25
Richardson, Irma M
NCT05582434: Experience With Topical Acne Treatment

Recruiting
1
72
US
Adapalene Gel, Differin, Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel, Differin and ONEXTON, adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day., Differin, Epsolay, Clindamycin
Wake Forest University Health Sciences, Bausch Health Americas, Inc.
Acne
05/25
11/25
NCT05570955: Deucravacitinib Adherence Study

Recruiting
N/A
40
US
Text reminder
Wake Forest University Health Sciences, Bristol-Myers Squibb
Psoriasis
07/25
12/25
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
Obeime, Ivie M
ASCEND, NCT05295732: The Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

Completed
3
209
Europe, Canada, US
TMB-001, Matching Vehicle
Timber Pharmaceuticals Inc., LEO Pharma
Ichthyosis
06/24
09/24

Download Options